Literature DB >> 21850598

Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions.

Thomas Eugster1, Regula Marti, Lorenz Gurke, Peter Stierli.   

Abstract

BACKGROUND: The appropriate role for surgery and endovascular therapy for severe intermittent claudication (IC) remains controversial. We present our results after infrainguinal autogenous bypass for severe IC more than 10 years ago giving a reasoned argument to perform vein bypass as the primary procedure for severe IC.
METHODS: Our prospectively designed database includes more than 1,000 infrainguinal bypasses following an all-autogenous policy. For this review only patients operated on for severe IC at least 10 years ago were included. The primary end points were survival and primary and assisted-primary patency rates.
RESULTS: From October 1988 until December 2000, 124 bypasses for IC were performed. Ninety-five patients were male and the mean age was 64.5 ± 10.8 years. Survival after 10 years was 50.3% according to life table analysis. Forty bypasses were to the supragenicular artery, 62 to the infragenicular popliteal artery, and 22 to the tibial artery. Thirty-day mortality was 0.8% (1 patient). The primary patency rate after 10 years was 63.5% and the assisted-primary patency rate 87.3%.
CONCLUSION: Infrainguinal venous bypass for severe IC has excellent long-term results. Our results are strong arguments against the liberal use of stenting long lesions of the femoropopliteal artery. Venous bypass remains the primary procedure for TASC C and D lesions in claudicants.

Entities:  

Mesh:

Year:  2011        PMID: 21850598     DOI: 10.1007/s00268-011-1237-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  Full metal jacket stenting of the superficial femoral artery: a retrospective review.

Authors:  Parth S Shah; Anil Hingorani; Enrico Ascher; Alexander Shiferson; Kapil Gopal; Daniel Jung; Natalie Marks; Theresa Jacob
Journal:  Ann Vasc Surg       Date:  2011-01       Impact factor: 1.466

2.  Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results.

Authors:  Hans Krankenberg; Ina Sorge; Thomas Zeller; Thilo Tübler
Journal:  Catheter Cardiovasc Interv       Date:  2005-01       Impact factor: 2.692

3.  Clinical outcomes and implications of failed infrainguinal endovascular stents.

Authors:  Ilia Gur; William Lee; Gabriel Akopian; Vincent L Rowe; Fred A Weaver; Steven G Katz
Journal:  J Vasc Surg       Date:  2011-01-22       Impact factor: 4.268

4.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

5.  Vascular surgical society of great britain and ireland: review of 94 tibial bypasses for intermittent claudication

Authors: 
Journal:  Br J Surg       Date:  1999-05       Impact factor: 6.939

6.  Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries.

Authors:  Schila Sabeti; Wolfgang Mlekusch; Jasmin Amighi; Erich Minar; Martin Schillinger
Journal:  J Endovasc Ther       Date:  2005-02       Impact factor: 3.487

7.  Stenting vs above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease.

Authors:  Hasan H Dosluoglu; Gregory S Cherr; Purandath Lall; Linda M Harris; Maciej L Dryjski
Journal:  J Vasc Surg       Date:  2008-08-09       Impact factor: 4.268

8.  Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score.

Authors:  Daniel M Ihnat; Son T Duong; Zachary C Taylor; Luis R Leon; Joseph L Mills; Kaoru R Goshima; Jose A Echeverri; Bulent Arslan
Journal:  J Vasc Surg       Date:  2008-04-18       Impact factor: 4.268

9.  Long-term results of infrageniculate bypass grafting using all-autogenous composite vein.

Authors:  Michael A Curi; Christopher L Skelly; David H Woo; Tina R Desai; Daniel Katz; James F McKinsey; Hisham S Bassiouny; Bruce L Gewertz; Lewis B Schwartz
Journal:  Ann Vasc Surg       Date:  2002-08-19       Impact factor: 1.466

10.  Femorotibial bypass for claudication: do results justify an aggressive approach?

Authors:  M S Conte; M Belkin; M C Donaldson; P Baum; J A Mannick; A D Whittemore
Journal:  J Vasc Surg       Date:  1995-06       Impact factor: 4.268

View more
  3 in total

Review 1.  Intermittent Claudication and Asymptomatic Peripheral Arterial Disease.

Authors:  Gerhard Rümenapf; Stephan Morbach; Andrej Schmidt; Martin Sigl
Journal:  Dtsch Arztebl Int       Date:  2020-03-13       Impact factor: 5.594

Review 2.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

Review 3.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.